Journal of Infection
Volume 64, Issue 2 , Pages 131-147 , February 2012

Clostridium difficile infection in HIV-seropositive individuals and transplant recipients

  • Paul J. Collini

      Affiliations

    • Department of Infection and Immunity, University of Sheffield Medical School and Sheffield Teaching Hospitals, Beech Hill Rd, Sheffield S10 2RX, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 0 114 271 2439; fax: +44 0 114 226 8898.
    • ,
  • Martijn Bauer

      Affiliations

    • Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, Leiden 2300 RC, Netherlands
    • ,
  • Ed Kuijper

      Affiliations

    • Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, Leiden 2300 RC, Netherlands
    • ,
  • David H. Dockrell

      Affiliations

    • Department of Infection and Immunity, University of Sheffield Medical School and Sheffield Teaching Hospitals, Beech Hill Rd, Sheffield S10 2RX, UK

,Accepted 6 December 2011.

References 

  1. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011 Jan 1;377(9759):63–73
  2. Raines DL, Lopez FA. Clostridium difficile infection in non-HIV-immunocompromised patients and in HIV-Infected patients. Curr Gastroenterol Rep. 2011 Aug;13(4):344–350
  3. Morris AM, Jobe BA, Stoney M, Sheppard BC, Deveney CW, Deveney KE. Clostridium difficile colitis: an increasingly aggressive iatrogenic disease?. Arch Surg. 2002 Oct;137(10):1096–1100
  4. Svenungsson B, Burman LG, Jalakas-Pornull K, Lagergren A, Struwe J, Akerlund T. Epidemiology and molecular characterization of Clostridium difficile strains from patients with diarrhea: low disease incidence and evidence of limited cross-infection in a Swedish teaching hospital. J Clin Microbiol. 2003 Sep;41(9):4031–4037
  5. Reddy S, Taori S, Poxton IR. Changes in laboratory and clinical workload for Clostridium difficile infection from 2003 to 2007 in hospitals in Edinburgh. Clin Microbiol Infect. 2010 Apr;16(4):340–346
  6. Herrera P, Cotera A, Fica A, Galdo T, Alvo M. High incidence and complications of Clostridium difficile diarrhea among patients with renal diseases. Rev Med Chil. 2003 Apr;131(4):397–403
  7. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002 Mar;235(3):363–372
  8. Dudukgian H, Sie E, Gonzalez-Ruiz C, Etzioni DA, Kaiser AM. C. difficile colitis–predictors of fatal outcome. J Gastrointest Surg. 2010 Feb;14(2):315–322
  9. Gellad ZF, Alexander BD, Liu JK, Griffith BC, Meyer AM, Johnson JL, et al. Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients. Transpl Infect Dis. 2007 Dec;9(4):276–280
  10. Barbut F, Petit JC. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect. 2001 Aug;7(8):405–410
  11. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007 Feb;28(2):140–145
  12. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009 Dec;15(12):1067–1079
  13. Deneve C, Janoir C, Poilane I, Fantinato C, Collignon A. New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents. 2009 Mar;33(Suppl. 1):S24–S28
  14. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005 Sep;5(9):549–557
  15. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005 Apr;18(2):247–263
  16. Poxton IR, McCoubrey J, Blair G. The pathogenicity of Clostridium difficile. Clin Microbiol Infect. 2001 Aug;7(8):421–427
  17. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009 Jul;7(7):526–536
  18. Ballard JD. Medical microbiology: a toxin contest. Nature. 2010 Oct 7;467(7316):665–666
  19. Kim H, Rhee SH, Kokkotou E, Na X, Savidge T, Moyer MP, et al. Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK. J Biol Chem. 2005 Jun 3;280(22):21237–21245
  20. Warny M, Keates AC, Keates S, Castagliuolo I, Zacks JK, Aboudola S, et al. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest. 2000 Apr;105(8):1147–1156
  21. Savidge TC, Urvil P, Oezguen N, Ali K, Choudhury A, Acharya V, et al. Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nat Med. 2011;17(9):1136–1141
  22. Meyer GK, Neetz A, Brandes G, Tsikas D, Butterfield JH, Just I, et al. Clostridium difficile toxins A and B directly stimulate human mast cells. Infect Immun. 2007 Aug;75(8):3868–3876
  23. Vilhardt F, Plastre O, Sawada M, Suzuki K, Wiznerowicz M, Kiyokawa E, et al. The HIV-1 Nef protein and phagocyte NADPH oxidase activation. J Biol Chem. 2002 Nov 1;277(44):42136–42143
  24. Rezzani R. Exploring cyclosporine A-side effects and the protective role-played by antioxidants: the morphological and immunohistochemical studies. Histol Histopathol. 2006 Mar;21(3):301–316
  25. Dalmarco EM, Budni P, Parisotto EB, Wilhelm Filho D, Frode TS. Antioxidant effects of mycophenolate mofetil in a murine pleurisy model. Transpl Immunol. 2009 Dec;22(1–2):12–17
  26. Varin A, Manna SK, Quivy V, Decrion AZ, Van Lint C, Herbein G, et al. Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. J Biol Chem. 2003 Jan 24;278(4):2219–2227
  27. Mangino G, Percario ZA, Fiorucci G, Vaccari G, Manrique S, Romeo G, et al. In vitro treatment of human monocytes/macrophages with myristoylated recombinant Nef of human immunodeficiency virus type 1 leads to the activation of mitogen-activated protein kinases, IkappaB kinases, and interferon regulatory factor 3 and to the release of beta interferon. J Virol. 2007 Mar;81(6):2777–2791
  28. Menor C, Fernandez-Moreno MD, Fueyo JA, Escribano O, Olleros T, Arriaza E, et al. Azathioprine acts upon rat hepatocyte mitochondria and stress-activated protein kinases leading to necrosis: protective role of N-acetyl-L-cysteine. J Pharmacol Exp Ther. 2004 Nov;311(2):668–676
  29. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000 May;47(2–3):119–125
  30. Shui H, Gao P, Si X, Ding G. Mycophenolic acid inhibits albumin-induced MCP-1 expression in renal tubular epithelial cells through the p38 MAPK pathway. Mol Biol Rep. 2010 Apr;37(4):1749–1754
  31. Andreucci M, Faga T, Lucisano G, Uccello F, Pisani A, Memoli B, et al. Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells. Chem Biol Interact. 2010 May 14;185(3):253–262
  32. Goppelt-Struebe M, Wolter D, Resch K. Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/PGE isomerase. Br J Pharmacol. 1989 Dec;98(4):1287–1295
  33. Martin M, Neumann D, Hoff T, Resch K, DeWitt DL, Goppelt-Struebe M. Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int. 1994 Jan;45(1):150–158
  34. Greenblatt MB, Aliprantis A, Hu B, Glimcher LH. Calcineurin regulates innate antifungal immunity in neutrophils. J Exp Med. 2010 May 10;207(5):923–931
  35. Jabs T. Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochem Pharmacol. 1999 Feb 1;57(3):231–245
  36. Um HD, Orenstein JM, Wahl SM. Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J Immunol. 1996 May 1;156(9):3469–3477
  37. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998 Jan 15;58(2):362–366
  38. von Knethen A, Callsen D, Brune B. Superoxide attenuates macrophage apoptosis by NF-kappa B and AP-1 activation that promotes cyclooxygenase-2 expression. J Immunol. 1999 Sep 1;163(5):2858–2866
  39. Munoz P, Giannella M, Alcala L, Sarmiento E, Fernandez Yanez J, Palomo J, et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer?. J Heart Lung Transplant. 2007 Sep;26(9):907–914
  40. West M, Pirenne J, Chavers B, Gillingham K, Sutherland DE, Dunn DL, et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplant. 1999 Aug;13(4):318–323
  41. Keven K, Basu A, Re L, Tan H, Marcos A, Fung JJ, et al. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis. 2004 Mar;6(1):10–14
  42. Sharma AK, Holder FE. Clostridium difficile diarrhea after use of tacrolimus following renal transplantation. Clin Infect Dis. 1998 Dec;27(6):1540–1541
  43. Manges AR, Labbe A, Loo VG, Atherton JK, Behr MA, Masson L, et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis. 2010 Dec 15;202(12):1877–1884
  44. Rea MC, Dobson A, O’Sullivan O, Crispie F, Fouhy F, Cotter PD, et al. Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A. 2011 Mar 15;108(Suppl. 1):4639–4644
  45. Jia JS, Huang XJ, Liu DH, Xiu LP, Zhang YC, Wu T, et al. Relationship between Clostridium difficile associated diarrhea and intestinal microecosystem disorder in patients received allogeneic hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):135–139
  46. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993 Jul;17(1):109–113
  47. Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, Ryder RW, et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis. 1983 Jul;148(1):93–100
  48. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000 Feb 10;342(6):390–397
  49. Mulligan ME, Miller SD, McFarland LV, Fung HC, Kwok RY. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis. 1993 Jun;16(Suppl. 4):S239–S244
  50. Johnson S, Gerding DN, Janoff EN. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis. 1992 Dec;166(6):1287–1294
  51. Sanchez-Hurtado K, Corretge M, Mutlu E, McIlhagger R, Starr JM, Poxton IR. Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls. J Med Microbiol. 2008 Jun;57(Pt 6):717–724
  52. Gryboski JD, Pellerano R, Young N, Edberg S. Positive role of Clostridium difficile infection in diarrhea in infants and children. Am J Gastroenterol. 1991 Jun;86(6):685–689
  53. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun. 1994 Feb;62(2):384–389
  54. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001 Jan 20;357(9251):189–193
  55. Aronsson B, Granstrom M, Mollby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection. 1985 May–Jun;13(3):97–101
  56. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2010 Jan 22;28(4):965–969
  57. Knight AK, Mayer L, Franks AG, Cunningham-Rundles C. Hypogammaglobulinemia with facial edema. PLoS Med. 2006 Dec;3(12):e475
  58. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010 Jan 21;362(3):197–205
  59. Moir S, Malaspina A, Ogwaro KM, Donoghue ET, Hallahan CW, Ehler LA, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10362–10367
  60. Conge AM, Tarte K, Reynes J, Segondy M, Gerfaux J, Zembala M, et al. Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1-disease. AIDS. 1998 Aug 20;12(12):1437–1449
  61. Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis. 2000 Feb;30(2):256–260
  62. Schalk E, Bohr UR, Konig B, Scheinpflug K, Mohren M. Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol. 2009 Jun 17;
  63. Apostolopoulou E, Raftopoulos V, Terzis K, Elefsiniotis I. Infection probability score: a predictor of Clostridium difficile-associated disease onset in patients with haematological malignancy. Eur J Oncol Nurs. 2010 Dec 2;
  64. Tunccan OG, Ulutan F, Karakus R. The frequency of Clostridium difficile toxin in neutropenic and non-neutropenic patients with antibiotic-associated diarrhea and analysis of the risk factors. Mikrobiyol Bul. 2008 Oct;42(4):573–583
  65. Toor AA, van Burik JA, Weisdorf DJ. Infections during mobilizing chemotherapy and following autologous stem cell transplantation. Bone Marrow Transplant. 2001 Dec;28(12):1129–1134
  66. Nomura K, Fujimoto Y, Yamashita M, Morimoto Y, Ohshiro M, Sato K, et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol. 2009;44(1):74–78
  67. Kirkpatrick ID, Greenberg HM. Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT. Radiology. 2003 Mar;226(3):668–674
  68. Kirkpatrick ID, Greenberg HM. Evaluating the CT diagnosis of Clostridium difficile colitis: should CT guide therapy?. AJR Am J Roentgenol. 2001 Mar;176(3):635–639
  69. Boland GW, Lee MJ, Cats AM, Gaa JA, Saini S, Mueller PR. Antibiotic-induced diarrhea: specificity of abdominal CT for the diagnosis of Clostridium difficile disease. Radiology. 1994 Apr;191(1):103–106
  70. Mahida YR, Galvin A, Makh S, Hyde S, Sanfilippo L, Borriello SP, et al. Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T-cell apoptosis. Infect Immun. 1998 Nov;66(11):5462–5469
  71. Modi N, Gulati N, Solomon K, Monaghan T, Robins A, Sewell HF, et al. Differential binding and internalisation of Clostridium difficile toxin A by human peripheral blood monocytes, neutrophils and lymphocytes. Scand J Immunol. 2011 May 19;
  72. Ryan A, Lynch M, Smith SM, Amu S, Nel HJ, McCoy CE, et al. A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog. 2011 Jun;7(6):e1002076
  73. Pulvirenti JJ, Gerding DN, Nathan C, Hafiz I, Mehra T, Marsh D, et al. Difference in the incidence of Clostridium difficile among patients infected with human immunodeficiency virus admitted to a public hospital and a private hospital. Infect Control Hosp Epidemiol. 2002 Nov;23(11):641–647
  74. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005 Sep 24-30;366(9491):1079–1084
  75. Kelly CP, LaMont JT. Clostridium difficile–more difficult than ever. N Engl J Med. 2008 Oct 30;359(18):1932–1940
  76. Wanke CA, Mayer H, Weber R, Zbinden R, Watson DA, Acheson D. Enteroaggregative Escherichia coli as a potential cause of diarrheal disease in adults infected with human immunodeficiency virus. J Infect Dis. 1998 Jul;178(1):185–190
  77. Mathewson JJ, Salameh BM, DuPont HL, Jiang ZD, Nelson AC, Arduino R, et al. HEp-2 cell-adherent Escherichia coli and intestinal secretory immune response to human immunodeficiency virus (HIV) in outpatients with HIV-associated diarrhea. Clin Diagn Lab Immunol. 1998 Jan;5(1):87–90
  78. Gordon MA, Kankwatira AM, Mwafulirwa G, Walsh AL, Hopkins MJ, Parry CM, et al. Invasive non-typhoid salmonellae establish systemic intracellular infection in HIV-infected adults: an emerging disease pathogenesis. Clin Infect Dis. 2010 Apr 1;50(7):953–962
  79. Mwachari C, Batchelor BI, Paul J, Waiyaki PG, Gilks CF. Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. J Infect. 1998 Jul;37(1):48–53
  80. Larsen IK, Gradel KO, Helms M, Hornstrup MK, Jurgens G, Mens H, et al. Non-typhoidal Salmonella and Campylobacter infections among HIV-positive patients in Denmark. Scand J Infect Dis. 2011 Jan;43(1):3–7
  81. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr. 2002 May 1;30(1):21–26
  82. Mastroianni A, Coronado O, Nanetti A, Valentini R, Manfredi R, Chiodo F. Nosocomial Clostridium difficile-associated diarrhea in patients with AIDS: a three-year survey and review. Clin Infect Dis. 1997 Sep;25(Suppl. 2):S204–S205
  83. Zulu I, Kelly P, Mwansa J, Veitch A, Farthing MJ. Contrasting incidence of Clostridium difficile and other enteropathogens in AIDS patients in London and Lusaka. Trans R Soc Trop Med Hyg. 2000 Mar–Apr;94(2):167–168
  84. Anastasi JK, Capili B. HIV and diarrhea in the era of HAART: 1998 New York state hospitalizations. Am J Infect Control. 2000 Jun;28(3):262–266
  85. Sanchez TH, Brooks JT, Sullivan PS, Juhasz M, Mintz E, Dworkin MS, et al. Bacterial diarrhea in persons with HIV infection, United States, 1992–2002. Clin Infect Dis. 2005 Dec 1;41(11):1621–1627
  86. Mainardi JL, Lacassin F, Guilloy Y, Goldstein FW, Leport C, Acar JF, et al. Low rate of Clostridium difficile colonization in ambulatory and hospitalized HIV-infected patients in a hospital unit: a prospective survey. J Infect. 1998 Sep;37(2):108–111
  87. Pulvirenti J, Mehra T, Hafiz I, DeMarais P, Marsh D, Kocka F, et al. Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients. Diagn Microbiol Infect Dis. 2002 DEC;44(4):325–330[Article]
  88. Hutin Y, Casin I, Lesprit P, Welker Y, Decazes JM, Lagrange P, et al. Prevalence of and risk factors for Clostridium difficile colonization at admission to an infectious diseases ward. Clin Infect Dis. 1997 May;24(5):920–924
  89. Barbut F, Meynard JL, Guiguet M, Avesani V, Bochet MV, Meyohas MC, et al. Clostridium difficile-associated diarrhea in HIV-infected patients: epidemiology and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Nov 1;16(3):176–181
  90. Hutin Y, Molina JM, Casin I, Daix V, Sednaoui P, Welker Y, et al. Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients. AIDS. 1993 Nov;7(11):1441–1447
  91. Tumbarello M, Tacconelli E, Leone F, Cauda R, Ortona L. Clostridium difficile-associated diarrhoea in patients with human immunodeficiency virus infection: a case-control study. Eur J Gastroenterol Hepatol. 1995 Mar;7(3):259–263
  92. Bouza E, Padilla B, Catalan P, Sanchez-Carrillo C, Blazquez R, Pelaez T. Diarrhea associated with Clostridium difficile: one-year experience in a general hospital. Rev Clin Esp. 1996 Jul;196(7):424–430
  93. DeMarais PL, Gertzen J, Weinstein RA. Nosocomial infections in human immunodeficiency virus-infected patients in a long-term-care setting. Clin Infect Dis. 1997 Nov;25(5):1230–1232
  94. Mody LR, Smith SM, Dever LL. Clostridium difficile-associated diarrhea in a VA medical center: clustering of cases, association with antibiotic usage, and impact on HIV-infected patients. Infect Control Hosp Epidemiol. 2001 Jan;22(1):42–45
  95. Buchner AM, Sonnenberg A. Medical diagnoses and procedures associated with clostridium difficile colitis. Am J Gastroenterol. 2001 Mar;96(3):766–772
  96. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother. 1998 May;41(Suppl. C):21–27
  97. Saddi VR, Glatt AE. Clostridium difficile-associated diarrhea in patients with HIV: a 4-year survey. J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):542–543
  98. Samie A, Obi CL, Franasiak J, Archbald-Pannone L, Bessong PO, Alcantara-Warren C, et al. PCR detection of Clostridium difficile triose phosphate isomerase (tpi), toxin A (tcdA), toxin B (tcdB), binary toxin (cdtA, cdtB), and tcdC genes in Vhembe district, South Africa. Am J Trop Med Hyg. 2008 Apr;78(4):577–585
  99. Willingham FF, Ticona Chavez E, Taylor DN, Bowen AB, Crane AR, Gottlieb AL, et al. Diarrhea and Clostridium difficile infection in Latin American patients with AIDS. Working group on AIDS in Peru. Clin Infect Dis. 1998 Sep;27(3):487–493
  100. Cappell MS, Philogene C. Clostridium difficile infection is a treatable cause of diarrhea in patients with advanced human immunodeficiency virus infection: a study of seven consecutive patients admitted from 1986 to 1992 to a university teaching hospital. Am J Gastroenterol. 1993 Jun;88(6):891–897
  101. Lu SS, Schwartz JM, Simon DM, Brandt LJ. Clostridium difficile-associated diarrhea in patients with HIV positivity and AIDS: a prospective controlled study. Am J Gastroenterol. 1994 Aug;89(8):1226–1229
  102. Zuckerman E, Kanel G, Ha C, Kahn J, Gottesman BS, Korula J. Low albumin gradient ascites complicating severe pseudomembranous colitis. Gastroenterology. 1997 Mar;112(3):991–994
  103. Beaugerie L, Ngo Y, Goujard F, Gharakhanian S, Carbonnel F, Luboinski J, et al. Etiology and management of toxic megacolon in patients with human immunodeficiency virus infection. Gastroenterology. 1994 Sep;107(3):858–863
  104. Steinlauf AF, Traube M, Neitlich JD, Cooney EL. Clostridium difficile colitis: a possible cause of unexplained elevation of serum alkaline phosphatase levels in patients with AIDS. Clin Infect Dis. 1998 May;26(5):1248–1249
  105. Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009 Dec;15(12):1053–1066
  106. Olofinlade O, Chiang C. Cytomegalovirus infection as a cause of pseudomembrane colitis: a report of four cases. J Clin Gastroenterol. 2001 Jan;32(1):82–84
  107. Younus F, Steigbigel RT. Images in clinical medicine. Nodular Clostridium difficile colitis. N Engl J Med. 2004 Mar 4;350(10):e9
  108. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005 Jun 1;40(11):1586–1590
  109. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005 Jun 1;40(11):1591–1597
  110. Kuijper EJ, Wilcox MH. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?. Clin Infect Dis. 2008 Jul 1;47(1):63–65
  111. HPA . Clostridium difficile Ribotyping Network (CDRN) for England and Northern Ireland 2009/2010 report. [28 November 2011]; Available from: 2011;http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1296681523205
  112. Pepin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol. 2007 Dec;102(12):2781–2788
  113. Cozart JC, Kalangi SS, Clench MH, Taylor DR, Borucki MJ, Pollard RB, et al. Clostridium difficile diarrhea in patients with AIDS versus non-AIDS controls. Methods of treatment and clinical response to treatment. J Clin Gastroenterol. 1993 Apr;16(3):192–194
  114. Barbut F, Depitre C, Delmee M, Corthier G, Petit JC. Comparison of enterotoxin production, cytotoxin production, serogrouping, and antimicrobial susceptibilities of Clostridium difficile strains isolated from AIDS and human immunodeficiency virus-negative patients. J Clin Microbiol. 1993 Mar;31(3):740–742
  115. Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother. 2002 Jun;46(6):1647–1650
  116. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009 Jun;58(6):403–410
  117. Alonso R, Gros S, Pelaez T, Garcia-de-Viedma D, Rodriguez-Creixems M, Bouza E. Molecular analysis of relapse vs re-infection in HIV-positive patients suffering from recurrent Clostridium difficile associated diarrhoea. J Hosp Infect. 2001 Jun;48(2):86–92
  118. van Kraaij MG, Dekker AW, Verdonck LF, van Loon AM, Vinje J, Koopmans MP, et al. Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant. 2000 Aug;26(3):299–303
  119. Nusair A, Jourdan D, Medcalf S, Marion N, Iwen PC, Fey PD, et al. Infection control experience in a cooperative care center for transplant patients. Infect Control Hosp Epidemiol. 2008 May;29(5):424–429
  120. Cox GJ, Matsui SM, Lo RS, Hinds M, Bowden RA, Hackman RC, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology. 1994 Nov;107(5):1398–1407
  121. Vigil K, Sheppard T, Adachi J, del Busto R. High incidence of Clostridium difficile-associated diarrhea (CDAD) in hematopoietic stem cell transplant (HSCT) patients during 2005. Int J Infect Dis. 2006 Jul;10:S30–S31[Meeting Abstract]
  122. Chopra T, Chandrasekar P, Salimnia H, Heilbrun LK, Smith D, Alangaden GJ. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant. 2011 Jan–Feb;25(1):E82–E87
  123. Ahmad S, Ali M, Guddati A, Kumar N, Kumar G. Clostridium difficile associated diarrhea is a predictor of mortality in nationwide hospitalized bone marrow transplant patients. Gastroenterology. 2011 May;140(5):S350–S355[Meeting Abstract]
  124. Tomblyn M, Gordon L, Singhal S, Tallman M, Williams S, Winter J, et al. Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplant. 2002 Oct;30(8):517–519
  125. Yuen KY, Woo PC, Liang RH, Chiu EK, Chen FF, Wong SS, et al. Clinical significance of alimentary tract microbes in bone marrow transplant recipients. Diagn Microbiol Infect Dis. 1998 Feb;30(2):75–81
  126. Dettenkofer M, Ebner W, Bertz H, Babikir R, Finke J, Frank U, et al. Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transplant. 2003 May;31(9):795–801
  127. Chakrabarti S, Lees A, Jones SG, Milligan DW. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant. 2000 Oct;26(8):871–876
  128. Dubberke ER, Reske KA, Srivastava A, Sadhu J, Gatti R, Young RM, et al. Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant. 2010 Mar–Apr;24(2):192–198
  129. Terada Y, Onishi Y, Kim S, Kami M, Mori S, Heike Y, et al. Clinical significance of positive Clostridium difficile (CD) toxin in the stool of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Blood. 2004 Nov 16;104(11):353B-B;[Meeting Abstract]
  130. Arango JI, Restrepo A, Schneider DL, Callander NS, Ochoa-Bayona JL, Restrepo MI, et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant. 2006 Mar;37(5):517–521
  131. Harter C, Schulze B, Goldschmidt H, Benner A, Geiss HK, Hoppe-Tichy T, et al. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant. 2006 Feb;37(4):373–379
  132. Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, et al. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2010 Dec 23;
  133. Bilgrami S, Feingold JM, Dorsky D, Edwards RL, Bona RD, Khan AM, et al. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999 May;23(10):1039–1042
  134. Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol. 1995 Jan;13(1):239–250
  135. Leger CS, Bredeson C, Kearns B, Bence-Bruckler I, Atkins H, Huebsch L. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant. 2000;6(2A):204–210
  136. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009 Mar;8(3):244–253
  137. Avery R, Pohlman B, Adal K, Bolwell B, Goldman M, Kalaycio M, et al. High prevalence of diarrhea but infrequency of documented Clostridium difficile in autologous peripheral blood progenitor cell transplant recipients. Bone Marrow Transplant. 2000 Jan;25(1):67–69
  138. Barton T, Collis T, Stadtmauer E, Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis. 2001 Feb 1;32(3):391–395
  139. Jillella AP, Ustun C, Robach E, Sertkaya D, DiPiro C, Kallab AM, et al. Infectious complications in patients receiving mobilization chemotherapy for autologous peripheral blood stem cell collection. J Hematother Stem Cell Res. 2003 Apr;12(2):155–160
  140. Therriault BL, Wilson JW, Barreto JN, Estes LL. Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline. Mayo Clin Proc. 2010 Aug;85(8):711–718
  141. Leung S, Metzger BS, Currie BP. Incidence of Clostridium difficile infection in patients with acute leukemia and lymphoma after allogeneic hematopoietic stem cell transplantation. Infect Control Hosp Epidemiol. 2010 Mar;31(3):313–315
  142. Chopra T, Alangaden G, Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti-Infective Ther. 2010 OCT;8(10):1113–1119[Review]
  143. Dubberke ER, Sadhu J, Gatti R, Reske KA, DiPersio JF, Devine SM, et al. Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system. Infect Control Hosp Epidemiol. 2007 Feb;28(2):208–211
  144. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ. 2004 Jul 6;171(1):51–58
  145. Turgeon DK, Novicki TJ, Quick J, Carlson L, Miller P, Ulness B, et al. Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. J Clin Microbiol. 2003 Feb;41(2):667–670
  146. Altclas J, Requejo A, Jaimovich G, Milovic V, Feldman L. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis. 2002 Mar 1;34(5):723
  147. Stelzmueller I, Goegele H, Biebl M, Wiesmayr S, Berger N, Tabarelli W, et al. Clostridium difficile colitis in solid organ transplantation–a single-center experience. Dig Dis Sci. 2007 Nov;52(11):3231–3236
  148. Theunissen C, Knoop C, Nonhoff C, Byl B, Claus M, Liesnard C, et al. Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation. Transpl Infect Dis. 2008 Jul;10(4):240–244
  149. Gunderson CC, Gupta MR, Lopez F, Lombard GA, LaPlace SG, Taylor DE, et al. Clostridium difficile colitis in lung transplantation. Transpl Infect Dis. 2008 Jul;10(4):245–251
  150. Wong NA, Bathgate AJ, Bellamy CO. Colorectal disease in liver allograft recipients – a clinicopathological study with follow-up. Eur J Gastroenterol Hepatol. 2002 Mar;14(3):231–236
  151. Hashimoto M, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Togashi J, et al. Clostridium difficile-associated diarrhea after living donor liver transplantation. World J Gastroenterol. 2007 Apr 14;13(14):2072–2076
  152. Albright JB, Bonatti H, Mendez J, Kramer D, Stauffer J, Hinder R, et al. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl Int. 2007 Oct;20(10):856–866
  153. Vahabzadeh B, Ringold D, Reske K, Dubberke E, Lisker-Melman M. Clostridium difficile infection (cdi) rates are higher in patients with liver disease and liver transplant recipients than patients without liver disease. Hepatology. 2008 Oct;48(4):795A–796A[Meeting Abstract]
  154. Ali M, Kumar N, Patel J, Ahmad S, Kumar G, Saeian K. Clostridium difficile infection in hospitalized liver transplant patients. Gastroenterology. 2011 May;140(5):S962–S966[Meeting Abstract]
  155. Wistrom J, Norrby SR, Myhre EB, Eriksson S, Granstrom G, Lagergren L, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother. 2001 Jan;47(1):43–50
  156. Samore MH, DeGirolami PC, Tlucko A, Lichtenberg DA, Melvin ZA, Karchmer AW. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis. 1994 Feb;18(2):181–187
  157. Yousuf K, Saklayen MG, Markert RJ, Barde CJ, Gopalswamy N. Clostridium difficile-associated diarrhea and chronic renal insufficiency. South Med J. 2002 Jul;95(7):681–683
  158. Cunney RJ, Magee C, McNamara E, Smyth EG, Walshe J. Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant. 1998 Nov;13(11):2842–2846
  159. Leung AC, Orange G, McLay A, Henderson IS. Clostridium difficile-associated colitis in uremic patients. Clin Nephrol. 1985 Nov;24(5):242–248
  160. Mitu-Pretorian OM, Forgacs B, Qumruddin A, Tavakoli A, Augustine T, Pararajasingam R. Outcomes of patients who develop symptomatic Clostridium difficile infection after solid organ transplantation. Transplant Proc. 2010 Sep;42(7):2631–2633
  161. Zerey M, Paton BL, Lincourt AE, Gersin KS, Kercher KW, Heniford BT. The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt). 2007 Dec;8(6):557–566
  162. Mori T, Kato J. Cytomegalovirus infection/disease after hematopoietic stem cell transplantation. Int J Hematol. 2010 May;91(4):588–595
  163. Feuchtinger T, Lang P, Handgretinger R. Adenovirus infection after allogeneic stem cell transplantation. Leuk Lymphoma. 2007 Feb;48(2):244–255
  164. Veroux M, Puzzo L, Corona D, Buffone A, Tallarita T, Murabito P, et al. Cytomegalovirus and Clostridium difficile ischemic colitis in a renal transplant recipient: a lethal complication of anti-rejection therapy?. Urol Int. 2007;79(2):177–179discussion 80
  165. Dahman M, Krell R, Brayman K, Sawyer RG, Cathro HP, Hagspiel KD, et al. Simultaneous Clostridium difficile-associated colitis and late-onset intestinal cytomegalovirus disease in a renal transplant recipient. Ann Transplant. 2010 Dec 22;15(4):72–76
  166. Yates B, Murphy DM, Fisher AJ, Gould FK, Lordan JL, Dark JH, et al. Pseudomembranous colitis in four patients with cystic fibrosis following lung transplantation. Thorax. 2007 Jun;62(6):554–556
  167. Yolken RH, Bishop CA, Townsend TR, Bolyard EA, Bartlett J, Santos GW, et al. Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med. 1982 Apr 29;306(17):1010–1012
  168. Kang G, Srivastava A, Pulimood A, Dennison D, Chandy M. Etiology of diarrhea in patients undergoing allogeneic bone marrow transplantation in south India. Transplantation. 2002 Apr 27;73(8):1247–1251[Article]

PII: S0163-4453(11)00580-9

doi: 10.1016/j.jinf.2011.12.003

Journal of Infection
Volume 64, Issue 2 , Pages 131-147 , February 2012

Article Tools

* Image Usage & Resolution